Sanctuary Advisors LLC Has $3.90 Million Stake in United Therapeutics Co. (NASDAQ:UTHR)

Sanctuary Advisors LLC reduced its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 1.2% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 11,077 shares of the biotechnology company’s stock after selling 140 shares during the quarter. Sanctuary Advisors LLC’s holdings in United Therapeutics were worth $3,902,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of UTHR. Newbridge Financial Services Group Inc. acquired a new position in shares of United Therapeutics in the 4th quarter valued at $25,000. Brooklyn Investment Group bought a new stake in United Therapeutics in the third quarter valued at about $33,000. Capital Performance Advisors LLP acquired a new position in United Therapeutics in the third quarter valued at about $82,000. MassMutual Private Wealth & Trust FSB lifted its stake in United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 58 shares during the period. Finally, Values First Advisors Inc. bought a new position in United Therapeutics during the third quarter worth about $90,000. 94.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

UTHR has been the subject of a number of recent analyst reports. UBS Group upped their price target on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. Argus upped their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. The Goldman Sachs Group lifted their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research report on Friday, November 1st. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Finally, HC Wainwright lifted their target price on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $382.08.

Insider Activity

In other United Therapeutics news, Director Louis W. Sullivan sold 26,209 shares of United Therapeutics stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total value of $9,781,722.98. Following the sale, the director now directly owns 5,051 shares in the company, valued at approximately $1,885,134.22. The trade was a 83.84 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Paul A. Mahon sold 7,700 shares of the stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $374.37, for a total transaction of $2,882,649.00. Following the transaction, the executive vice president now owns 36,710 shares of the company’s stock, valued at approximately $13,743,122.70. This represents a 17.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 124,164 shares of company stock worth $45,398,793 over the last ninety days. Insiders own 11.90% of the company’s stock.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $361.10 on Friday. United Therapeutics Co. has a 52 week low of $214.75 and a 52 week high of $417.82. The stock’s 50 day moving average price is $362.68 and its two-hundred day moving average price is $360.19. The stock has a market capitalization of $16.12 billion, a price-to-earnings ratio of 15.86, a PEG ratio of 0.99 and a beta of 0.57.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.